Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine

Journal of Clinical Investigation

Volumn 90, Issue 2, 1992, Pages 412-420

  Hone, David M ^a,b   Tacket, Carol O ^a   Harris, Andrea M ^a   Kay, Bradford ^a   Losonsky, Genevieve ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Auxotroph; Macrophage; Salmonella; Typhoid; U937 monocytes

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; TYPHOID VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCING CELL; ANTIGEN SPECIFICITY; ARTICLE; ATTENUATION; BILE; BLOOD CULTURE; DUODENUM FLUID; FECES CULTURE; FEVER; GROWTH CURVE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SALMONELLA TYPHI; SEROLOGY; TYPHOID FEVER; VACCINATION; VOLUNTEER;

ANTIBODIES, BACTERIAL; ANTIBODY-PRODUCING CELLS; BACTERIAL VACCINES; CELLS, CULTURED; DRUG EVALUATION; FEVER; HUMAN; IN VITRO; JEJUNUM; MACROPHAGES; SALMONELLA TYPHI; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TYPHOID FEVER; VACCINATION; VACCINES, ATTENUATED;

EID: 0026775501     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI115876     Document Type: Article

References (56)

1. Institute of Medicine. 1986. Prospects for immunizing against Salmonella typhi. In New Vaccine Development: Establishing Priorities. National Academy Press, Washington, DC. Appendix D-14, 1-10.
2. World Health Organization. 1987. In Biomedical and Epidemiological Research Priorities of Global Scientific Working Groups. WHO Publication WHO/ CDD/RES86.8rev. 1.
3. Hone, D. M., S. R. Attridge, B. Forrest, R. Morona, D. Daniels, J. T. LaBrooy, R. C. Bartholomeusz, D. J. Shearman, and J. Hackett. 1988. A galE, via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. 56:1326-1333.
4. Levine, M. M., D. Herrington, J. R. Murphy, J. G. Morris, G. Losonsky, B. Tall, A. A. Lindberg, S. Svenson, S. Baquar, M. F. Edwards et al. 1987. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J. Clin. Invest. 79:888-902.
5. Levine, M. M., D. M. Hone, B. A. D. Stocker, and M. Cadoz. 1990. Vaccines to prevent typhoid fever. In New Generation Vaccines. G. Woodrow and M. M. Levine, editors. Marcel Dekker, Inc., New York. 269-287.
6. Formal, S. B., L. S. Baron, D. J. Kopecko, O. Washington, C. Powell, and C. A. Life. 1981. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a vaccine strain. Infect. Immun. 34:746-750.
7. Clements, J. D., and S. El-Morshidy. 1984. Construction of a potential live oral bivalent vaccine for typhoid fever and cholera- Escherichia coli-related diarrheas. Infect. Immun. 46:564-569.
8. + cytotoxic T cells. J. Exp. Med. 172:1083-1090.
9. Wu, J. Y., S. Newton, A. Judd, B. Stocker, and W. S. Robinson. 1989. Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella. Proc. Natl. Acad. Sci. USA. 86:4726-4730.
10. Bacon, G. A., T. W. Burrows, and M. Yates. 1950. The effects of biochemical mutation on the virulence of Bacterium typhosum: the virulence of mutants. Br. J. Exp. Pathol. 31:714-724.
11. Hoiseth, S. K., and B. A. D. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (Lond). 291:238-239.
12. Edwards, M. F., and B. A. D. Stocker. 1988. Construction of delaroA his delpur strains of Salmonella typhi. J. Bacteriol. 170:3991-3995.
13. Stocker, B. A. D. 1988. Auxotrophic Salmonella typhi as live vaccine. Vaccine. 6:141-145.
14. Eisenstein, T. K., L. M. Killar, B. A. D. Stocker, and B. M. Sultzer. 1984. Cellular immunity induced by avirulent Salmonella in LPS-defective C3H/HeJ mice. J. Immunol. 133:958-961.
15. O'Callaghan, D., D. Maskell, F. Y. Liew, C. S. F. Easmon, and G. Dougan. 1988. Characterization of aromatic- and purine-dependent Salmonella typhimurium: attenuation, persistence, and ability to induce protective immunity in Balb/ c mice. Infect. Immun. 56:419-423.
16. Smith, B. P., M. Reina-Guerra, B. A. D. Stocker, S. K. Hoiseth, and E. H. Johnson. 1984. Vaccination of calves against Salmonella dublin with aromatic-dependent Salmonella typhimurium. Am. J. Vet. Res. 45:1858-1861.
17. Smith, B. P., M. Reina-Guerra, S. K. Hoiseth, B. A. D. Stocker, F. Haba-sha, E. Johnson, and F. Merritt. 1984. Aromatic-dependent Salmonella typhimurium as modified vaccines for calves. Am. J. Vet. Res. 45:59-66.
18. Sigwart, D. F., B. A. D. Stocker, and J. D. Clements. 1989. Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect. Immun. 57:1858-1861.
19. Sanderson, K. E., and J. A. Hurley. 1984. Linkage map of Salmonella typhimurium. In Escherichia coli and Salmonella typhimurium. Cellular and Molecular Biology. F. Neidhardt, J. L. Ingraham, K. B. Low, B. Magasanik, M. Schaechter, and H. E. Umbarger, editors. American Society for Microbiology, Washington, DC. 877-918.
20. Dougan, G., S. Chatfield, D. Pickard, J. Bester, D. O'Callaghan, and D. Maskell. 1988. Construction and characterization of vaccine strains of Salmonella harboring mutations in two different aro genes. J. Infect. Dis. 158:1329-1335.
21. Miller, I. A., S. Chatfield, G. Dougan, L. De Silva, H. S. Joysey, and C. E. Hormaeche. 1989. Bacteriophage P22 as a vehicle for transducing cosmid gene banks between smooth strains of Salmonella typhimurium: use in identifying a role for aroD in attenuating virulent Salmonella strains. Mol. Gen. Genet. 215:312-316.
22. Hone, D. M., A. M. Harris, S. Chatfield, G. Dougan, and M. M. Levine. 1991. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine. 9:810-816.
23. Sundstrom, C., and K. Nilsson. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int. J. Cancer. 17:565-577.
24. Buchmeier, N. A., and F. Heffron. 1989. Intracellular survival of wild-type Salmonella typhimurium and macrophage-sensitive mutants in diverse populations of macrophages. Infect. Immun. 57:1-7.
25. Van De Verg, L., D. A. Herrington, J. R. Murphy, S. S. Wasserman, S. B. Formal, and M. M. Levine. 1990. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect. Immun. 58:2002-2004.
26. Wong, K. H., and J. C. Feeley. 1972. Isolation of Vi antigen and a simple method for its measurement. Appl. Microbiol. 24:628-633.
27. Ikeda, T., R. Kamiya, and S. Yamaguchi. 1983. Excretion of flagellin by a short-flagella mutant of Salmonella typhimurium. J. Bacteriol. 153:506-510.
28. Levine, M. M., C. Ferruccio, R. E. Black, C. O. Tacket, R. Germanier, and the Chilean Typhoid Committee. 1989. Progress in vaccines against typhoid fever. Rev. Infect. Dis. 11(Suppl. 3):S552-S567.
29. Levine, M. M., H. L. DuPont, R. B. Hornick, M. J. Snyder, W. Woodward, R. H. Gilman, and J. P. Libonati. 1976. Attenuated, streptomycin-dependent Salmonella typhi oral vaccine: potential deleterious effects of lyophilization J. Infect. Dis. 133:424-429.
30. Hornick, R. B., S. E. Greisman, T. E. Woodward, H. L. Du Pont, A. T. Dawkins, and M. J. Snyder. 1970. Typhoid fever: pathogenesis and immunological control. N. Engl. J. Med. 283:686-691.
31. Gilman, R. H., R. B. Hornick, W. E. Woodward, H. L. DuPont, M. J. Snyder, M. M. Levine, and J. P. Libonati. 1977. Evaluation of a UDP-glucose-4epimeraseless mutant of Salmonella typhi as a live oral typhoid vaccine. J. Infect. Dis. 136:717-723.
32. Snyder, M. J., R. B. Hornick, F. R. McCrumb, L. J. Morse, and T. E. Woodward. 1963. Asymptomatic typhoidal bacteremia in volunteers. Antimicrob. Agents Chemother. 7:604-607.
33. Dragunsky, E. M., E. Rivera, H. D. Hochstein, and I. S. Levenbook. 1990. In vitro characterization of Salmonella typhi mutant strains for live oral vaccines. Vaccine. 8:263-268.
34. Stocker, B. A. D., and H. Makela. 1986. Genetic determinants of bacterial virulence, with special reference to Salmonella. Curr. Top. Microbiol. Immunol. 124:149-172.
35. Milhous, W. K., N. F. Weatherly, J. H. Bowdre, and R. E. Desjardins. 1985. In vitro activities of an mechanisms of resistance to antifolate antimalarial drugs. Antimicrob. Agents Chemother. 27:525-530.
36. Hoiseth, S. 1983. PhD. Thesis. Stanford University, Palo Alto, CA.
37. Benjamin, W. H., C. L. Tumbough, B. S. Posey, and D. B. Briles. 1989 The inability of Salmonella typhimurium to produce siderophore enterobactin is not a virulence factor in mouse typhoid. Infect. Immun. 50:392-397.
38. Olitzki, A. 1972. The natural resistance to infections caused by enteric pathogens. In Enteric Fevers: Causing Organisms and Host's Reactions. S. Karger, New York. 78-182.
39. Greisman, S. E., R. B. Hornick, H. N. Wagner, W. E. Woodward, and T. E. Woodward. 1969. The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J. Clin. Invest. 48:613-629.
40. Tully, J. G., S. Gaines, and W. D. Tigertt. 1965. Studies on infection in experimental typhoid fever. VI. Response of chimpanzees to endotoxin and the effect of tolerance on resistance to oral challenge. J. Infect. Dis. 115:445-455.
41. Kelly, S., and R. Curtiss III. 1987. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. 55:3035-3043.
42. + gene product. Mol. Gen. Genet. 155:77-85.
43. Miller, S. I., A. M. Kukral, and J. Mekalanos. 1989. A two-component regulatory system (phoP phoQ) controls Salmonella virulence. Proc. Natl. Acad. Sci. USA. 86:5054-5058.
44. Miller, S. I., and J. J. Mekalanos. 1990. Constitutive expression of the PhoP regulon attenuates Salmonella virulence and survival within macrophages. J. Bacteriol. 172:2485-2490.
45. Galan, J. E., and R. Curtiss III. 1989. Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microbial Pathol. 6:433-443.
46. Johnson, K., I. Charles, G. Dougan, D. Pickard, P. O'Gaora, G. Costa,T. Ali, I. Miller, and C. Hormaeche. 1991. The role of a stress-response protein in Salmonella typhimurium virulence. Mol. Microbiol. 5:401-407.
47. Buchmeier, N. A., and F. Heffron. 1990. Induction of Salmonella stress proteins upon infection of macrophages. Science (Wash. DC). 248:730-732.
48. Felix, A., S. S. Bhatnager, and R. M. Pitt. 1934. Observations on the properties of the Vi antigen of Bacillus typhosus. Br. J. Exp. Pathol. 15:346-354.
49. Johnson, F. M., B. Krauskopf, and L. S. Baron. 1965. Genetic mapping of Vi and somatic determinants in Salmonella. J. Bacteriol. 90:302-308.
50. Felix, A. and R. M. Pitt. 1951. The pathogenic and immunogenic activities of Salmonella typhi in relation to its antigenic constituents. J. Hyg. 49:92110.
51. Tacket, C. O., G. Losonsky, D. N. Taylor, L. S. Baron, D. Kopecko, S. Cryz, and M. M. Levine. 1991. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. J. Infect. Dis. 163:901-904.
52. Losonsky, G. A., C. Fereccio, K. L. Kotloff, S. Kaintuck, J. B. Robbins, and M. M. Levine. 1987. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers. J. Clin. Microbiol. 25:2266-2269.
53. Acharya, I. L., C. U. Lowe, R. Thapa, V. L. Gurubacharya, M. B. Shretha, M. Cadoz, D. Schulz, J. Armand, D. A. Bryla, B. Trollfors, et at. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N. Engl. J. Med. 317:1101-1104.
54. Tacket, C. O., B. Forrest, R. Morona, S. R. Attridge, J. LaBrooy, B. D. Tall, M. Reymann, D. Rowley, and M. M. Levine. 1990. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect. Immun. 58:1620-1627.
55. Kantele, A., and P. H. Makela. 1991. Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21 a vaccine. Vaccine. 9:423-427.
56. Kantele, A., J. M. Kantele, H. Arvilommi, and P. H. Makela. 1991. Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine. 9:428-431.